Rimonabant and Type 2 Diabetes
Here’s more news on Acomplia (rimonabant) from Sanofi-Aventis.
Benefited Patients with Type 2 Diabetes by Improving Blood Sugar Control - FierceBiotech:
Recently released data showed that Rimonabant a cannabinoid type 1 (CB1) receptor blocker helped patients control their sugar levels. It should be noted that these were type 2 patients who were not undergoing other treatments. THe A1C levels(a long term measure of how well blood sugar is controlled) showed small but significant decreases when treated with 20 mg of Rimonabant per day.
It will be interesting to see where this goes since the FDA issued an approvable letter and Sanofi gave their response. There really isn’t much there just that they will work closely with the FDA on its future development.
My best guess is this won’t have any impact on the questions the FDA asked since this study was likely underway long before the Feb approvable letter from the FDA.
Technorati Tags: Acomplia, Rimonabant, Sanofi-Aventis
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
